

WEBINAR – March 19, 2014
PA 14-01: Accelerated Development Pathway
Questions and Answers

Questions	Answers
1. What is the evaluation process for the LOI?	Applications at the LOI stage are evaluated internally by science and review staff solely for eligibility, based on the requirements set forth in the PA. An application must meet the required eligibility criteria in order to proceed to the application stage for review.
2. What are the guidelines for clinical sites? Do all the sites need to be in California?	For any clinical trial that is part of the proposed project, at least one of the clinical sites implementing the protocol must be in California.
3. Can we add a Co-PI to the new application?	A team cannot add an additional co-PI, although additional collaborators and consultants may be added as key personnel.
4. What are the requirements for the PI?	The PI must have an M.D., Ph.D. or equivalent degree to be eligible. CIRM expects that it will be the same PI as listed on the Parent Award and that at least the percent effort committed to activities on the Parent Award will be maintained for additional activities supported under PA 14-01.
5. How many applications for the Accelerated Pathway may I submit?	Each PI may submit a single application for PA 14-01 at this time. CIRM expects to offer future opportunities to compete for selection into the Accelerated Pathway. Teams not selected at this time may apply again during future calls.
6. Does the timeline for the Accelerated Pathway need to coincide with the Parent Award timeline? For example, our grant ends in 2017 therefore do we structure the accelerated pathway grant to end at the same time?	Activities proposed for PA 14-01 should be designed to accelerate the progress on the Parent Award. Activities that support the clinical trial funded under the Parent Award would be expected to fall within the duration of the Parent Award. A follow-on clinical trial would be funded as a separate award and could extend longer than the duration of the Parent Award; however, the goal of the Accelerated Development Pathway is to promote programs that may demonstrate clinical proof of concept during, or before, the year 2017.